Publication | Closed Access

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

OncologyMedicineVarious Solid TumorsPharmacotherapyAnti-cancer AgentPopulation PharmacokineticsCancer TreatmentPharmacologyRadiation OncologyCancer Research